TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06340841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Incentives
Description: The participant receives incentives directly if they complete an activity on a given day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Restorative Incentives
Description: The participant receives incentives directly if they complete an activity on a given day. They are given an additional incentive to return to completing activities if they did not complete an activity on a prior day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charity Incentives
Description: The participant earns compensation for charity if they complete an activity on a given day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charity Restorative Incentives
Description: The participant earns compensation for charity if they complete an activity on a given day. They are given an additional incentive for charity to return to completing activities if they did not complete an activity on a prior day.
Study: NCT05198063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cells)
Description: At 6 months after the basic immunization (window period ± 1 month), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
Study: NCT05091541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
Description: CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
Study: NCT06445803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
Description: CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
Description: CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)
Study: NCT05207657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lentiviral vector transduced CD34+ cells
Description: Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
Study: NCT05537818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVPI Device
Description: The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app

Intervention type: DEVICE
Group type: OTHER
Intervention: AVPI Device
Description: The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVPI Device
Description: The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app
Study: NCT06074224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep assessment score
Description: The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Score
Description: The patients in the control group will include those for whom their clinician was not given their sleep questionnaire result before the visit.
Study: NCT04758468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based pelvic floor muscle training
Description: Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based pelvic floor muscle training
Description: The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks.
Study: NCT06119308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzodiazepine Medication Taper with Cognitive Behavioral Therapy
Description: Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing (led by pharmacist/clinician/psychologist) over a 10-week Trial.
Study: NCT04688242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anal dilatation per anus
Description: Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus
Description: Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
Study: NCT05970627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Perioperative Toripalimab, 240 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study: NCT04762381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: 24 mg dexamethasone infused peroperatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05072873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
Study: NCT06102265

Intervention type: PROCEDURE
Intervention: sterilization
Description: the use of sterilization methods and the reuse of gowns

Intervention type: PROCEDURE
Intervention: sterilization
Description: the use of sterilization methods and the reuse of gowns
Study: NCT05089617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699.
Study: NCT05117138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMT-116 CAR-T cells
Description: 1. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~2. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMT-253 CAR-T cells
Description: 1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells.~3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum).
Study: NCT05681806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure AAS
Description: A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure AAS
Description: A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: 5g creatine monohydrate
Study: NCT04901650

Intervention type: DIAGNOSTIC_TEST
Intervention: Survey
Description: A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
Study: NCT05102279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Giving subjects different phosphorus diets at different stages of the trial
Description: Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Giving subjects different phosphorus diets at different stages of the trial
Description: Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
Study: NCT06125613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: In reality, there will not be 200 trials but 40, and no painful stimulus will be delivered. The objective is only to make the subject afraid of making a movement when the red stimulus appears, and for us to compare the situation afraid to move to that where there is no reason to be afraid in terms of corticocortical influences. The subject will then be invited, during the second experimental series, to perform the movements previously described. Whether the preparatory signal for movement is red or green, it will be followed with a delay of 500ms by a test stimulus alone (ST) or by a doublet of SC+ST stimulation. This stimulation will therefore occur during the motor programming period during which it has been shown in the literature that the pIPS exerts a facilitatory action on the primary motor cortex at a latency of 4 ms. In total, 10 ST and 10 SC-ST doublets will be delivered during the experimental series for each of the two colors, i.e. 40 stimulations in total.
Study: NCT06309108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Booklet
Description: The education group was given training with a education booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality Group
Description: The second of the intervention group was trained with augmented reality. Patients were able to see the augmented reality element with the 3DQR application.
Study: NCT05651776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy, Exercise
Description: Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
Study: NCT04629703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib
Description: Fostamatinib (150 mg twice daily) for 14 days and Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (twice daily) for 14 days and Standard of Care
Study: NCT06456632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Su Jok Therapy
Description: Su Jok Therapy
Study: NCT06405503

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION - OBSERVATIONAL ONLY

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION - OBSERVATIONAL ONLY
Study: NCT05303779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Interventions of Eye Muscles
Description: Application of eye exercise for improving eye control post strabismus surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication and eye glasses
Description: medication and eye glasses used post strabismus surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication and eye glasses
Description: medication and eye glasses used post strabismus surgery
Study: NCT05776030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Speed Ergonomic Wheelchair
Description: Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~1. 2:3~2. 1:1~3. 3:2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Speed Ergonomic Wheelchair
Description: The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Speed Ergonomic Wheelchair
Description: The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
Study: NCT05046054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation
Description: transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Description: Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
Study: NCT05586594

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)
Description: Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
Study: NCT06150365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSX01-TCRT cell therapy
Description: Patient autologous T cell therapy
Study: NCT05204225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet Application
Description: Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
Study: NCT05177458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% maximum heart rate) for 30 minutes on a treadmill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at 40-50% of maximum heart rate) for 30 minutes.
Study: NCT06497244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro osteo-perforation
Description: the patient will receive miniscrew micro osteo-perforation in one side every month with molar distalization and the other side the distalization without micro osteo-perforation
Study: NCT05311202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-volume moderate-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
Study: NCT06143735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efgbemalenograstim alfa
Description: Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgbemalenograstim alfa
Description: Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
Study: NCT05311202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-volume moderate-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-volume moderate-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-volume low-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Reading a book related to cognitive function \& exercise for 40 minutes